Morelli, A., Comeglio, P., Filippi, S., Sarchielli, E., Cellai, I., Vignozzi, L., Yehiely-Cohen, R., Maneschi, E., Gacci, M., Carini, M., Adorini, L., Vannelli, G.B. and Maggi, M. (2012) Testosterone and Farnesoid X Receptor Agonist INT-747 Counteract High Fat Diet-Induced Bladder Alterations in a Rabbit Model of Metabolic Syndrome. The Journal of Steroid Biochemistry and Molecular Biology, 132, 80-92.
http://dx.doi.org/10.1016/j.jsbmb.2012.02.007

has been cited by the following article:

• TITLE: Proteolytic Enzyme Combination Reduces Inflammation and Oxidative Stress and Improves Insulin Sensitivity in a Model of Metabolic Syndrome

  AUTHORS: Tetiana V. Talaieva, Victor V. Bratus

  KEYWORDS: Metabolic Syndrome, Systemic Enzyme Therapy, Wobenzym, Protease, Inflammation, CRP

  JOURNAL NAME: Advances in Enzyme Research, Vol.3 No.1, March 2, 2015

  ABSTRACT: Chronic, low-level inflammation may be an independent marker of Metabolic Syndrome (MetS). Systemic Enzyme Therapy (SET), the oral administration of proteolytic enzymes, is safe and effective in the management of inflammation. Therefore, the effects of SET, as Wobenzym®, on the prevention and treatment of inflammation and other metabolic risk factors were assessed in a rabbit model of diet-induced MetS. Animals were fed a lipid-enriched diet for 8 weeks during which they were administered a vehicle control (control group) or Wobenzym either throughout the study period (prevention group) or beginning at the 5th week, after the development of biomarkers of MetS (treatment group). At the 8th week, both prevention and treatment groups demonstrated improved insulin sensitivity relative to the control group and reduced serum C-reactive protein (CRP) and glycosylated hemoglobin (HbA1c, P